Sivasakthi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 20-06-2024
- Paid Up Capital ₹ 2.60 M
as on 20-06-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.40 Cr
as on 20-06-2024
- Revenue 44.18%
(FY 2019)
- Profit 28.47%
(FY 2019)
- Ebitda 54.56%
(FY 2019)
- Net Worth 105.51%
(FY 2019)
- Total Assets 2.93%
(FY 2019)
About Sivasakthi Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.60 M.
The company currently has active open charges totaling ₹1.40 Cr.
Rajanayaki Ganesan and Ilango serve as directors at the Company.
- CIN/LLPIN
U36900TZ2016PTC022412
- Company No.
022412
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Mar 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sivasakthi Pharmaceuticals Private Limited offer?
Sivasakthi Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Cough Syrup, Diabetic Herbal Medicine, Diabetic Herbal Tablets & Capsules, Pharmaceutical Medicine, Psoriasis Medicine, Cough Medicine, Herbal Capsules, Herbal Sexual Health Supplement, Sperm Count Booster Supplement.
Who are the key members and board of directors at Sivasakthi Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajanayaki Ganesan  | Director | 18-Mar-2016 | Current |
| Ilango | Director | 18-Mar-2016 | Current |
Financial Performance of Sivasakthi Pharmaceuticals.
Sivasakthi Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 44.18% increase. The company also saw a substantial improvement in profitability, with a 28.47% increase in profit. The company's net worth Soared by an impressive increase of 105.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sivasakthi Pharmaceuticals?
In 2019, Sivasakthi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 07 Jan 2022 | ₹1.40 Cr | Open |
How Many Employees Work at Sivasakthi Pharmaceuticals?
Unlock and access historical data on people associated with Sivasakthi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sivasakthi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sivasakthi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
